Xspray Pharma AB 2025 Annual Report
Company: Xspray Pharma AB
Sector: Manufacturing
Country: Sweden
Year: 2025
Type: Annual Report
Pages: 90
The report describes Xspray Pharma's 2025 progress toward commercialization, including FDA reviews of Dasynoc and XS003 nilotinib and a first out-licensing agreement with Handa Therapeutics. It reports that the Group had 25 employees at year-end and remained pre-commercial with no net sales. Sustainability disclosures focus on patients, partnerships, employees and environmental measures such as energy efficiency, waste reduction and reclaimed CO2 in manufacturing.
Data Services
From bulk PDFs to structured indicators and machine-readable documents.